Key Highlights

  • Paysign (NASDAQ:PAYS) closed down 18.94% on November 10, 2026 after disclosing that a plasma customer will move payment processing for 113 centers to another provider by year-end.
  • Third-quarter Revenue rose 43% to a record USD 30.8 million, led by pharma revenue that more than doubled to USD 16.62 million.
  • The departing centers produced USD 11.3 million of revenue and USD 5.2 million of Gross Profit over the past 12 months, with a fourth-quarter hit of about USD 1.5 million in revenue.
  • The company kept 2026 revenue guidance at USD 114.0 million to USD 117.0 million and raised its profit outlook, including adjusted EBITDA of USD 38.5 million to USD 40.0 million.

Why a Record Quarter Was Not Enough

Paysign (NASDAQ:PAYS) runs two main businesses: prepaid cards that plasma collection centers use to pay donors, and patient affordability programmes that help drug companies deliver co-pay assistance. The third quarter was its best ever. Revenue grew 42.6% to USD 30.80 million, gross Margin widened to 64.7% from 56.3%, Operating Margin rose to 23.8% and Net Income tripled to USD 6.74 million, or USD 0.11 per diluted share. Adjusted EBITDA more than doubled to USD 10.98 million. Yet the loss of 113 plasma centers, about a fifth of its network, was the focus for investors. The plasma Business is a long-standing source of steady, high-margin revenue, and the departing centers generated USD 11.3 million of revenue over the last year, more than a third of the plasma segment's annual run rate. Plasma revenue rose 7.5% to USD 13.83 million in the quarter, but the center count had already fallen to 562 from 595, and the company now expects to finish the year with only 445 to 450 centers.

The Pharma Business Is the Growth Engine

The offset is the pharma segment, which grew 109.8% in the quarter. The company runs 167 active patient affordability programmes, having added 62 net programmes over the last 12 months, and expects to exit 2026 with 190 to 195. Drug makers use these programmes to help patients afford branded medicines, and Demand has grown as co-pay costs rise and insurers tighten coverage. Chief executive Mark Newcomer described patient affordability as a compounding business, since each new programme adds recurring revenue. Chief financial officer Jeff Baker noted that results finished above the top of guidance. The Balance Sheet is clean, with USD 34.54 million of cash and no bank debt, and the company raised its full-year targets for gross margin of 63.5% to 64.5%, net income of USD 23.0 million to USD 24.0 million and Diluted Earnings per Share of USD 0.37 to USD 0.38.

What to Watch

The key question is whether the plasma loss marks the start of a broader trend or a single customer decision. Plasma operators have consolidated, and larger groups may seek to standardise their payment systems. Investors in Paysign (NASDAQ:PAYS) will watch 2027 guidance for the size of the plasma revenue gap, the pace of new pharma programmes and margins as the business mix shifts. Strong pharma growth could replace the lost revenue within a year, but the stock is likely to remain sensitive to any further customer news. A further shift in customer mix would affect the margin profile. Regulatory changes to co-pay assistance rules would also affect the pharma business.

Where Things Stand

Paysign fell 18.94% after a customer said it will move 113 plasma centers to another provider, even though third-quarter revenue rose 43% to a record USD 30.8 million and profit guidance rose. The pharma affordability business, growing more than 100%, is now the main driver. The size of the plasma gap in 2027 and new programme wins will decide how quickly the stock recovers.